Ignite Creation Date:
2025-12-24 @ 12:56 PM
Ignite Modification Date:
2025-12-27 @ 10:13 PM
Study NCT ID:
NCT01622361
Status:
UNKNOWN
Last Update Posted:
2013-09-30
First Post:
2012-06-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D004358', 'term': 'Drug Therapy'}, {'id': 'D013629', 'term': 'Tamoxifen'}], 'ancestors': [{'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D013267', 'term': 'Stilbenes'}, {'id': 'D001597', 'term': 'Benzylidene Compounds'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 290}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2012-06'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-09', 'completionDateStruct': {'date': '2016-02', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2013-09-26', 'studyFirstSubmitDate': '2012-06-13', 'studyFirstSubmitQcDate': '2012-06-15', 'lastUpdatePostDateStruct': {'date': '2013-09-30', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2012-06-19', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2016-02', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Response Rate', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'Pathologic complete response', 'timeFrame': '6 months'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Neoadjuvant', 'endocrine therapy', 'premenopausal', 'hormone responsive', 'HER2 negative', 'lymph node positive'], 'conditions': ['Breast Cancer']}, 'referencesModule': {'references': [{'pmid': '34660302', 'type': 'DERIVED', 'citation': 'Gwark S, Noh WC, Ahn SH, Lee ES, Jung Y, Kim LS, Han W, Nam SJ, Gong G, Kim SO, Kim HJ. Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. Front Oncol. 2021 Sep 30;11:741120. doi: 10.3389/fonc.2021.741120. eCollection 2021.'}, {'pmid': '34277393', 'type': 'DERIVED', 'citation': 'Gwark S, Ahn SH, Noh WC, Lee ES, Jung Y, Kim LS, Han W, Nam SJ, Gong G, Kim SO, Kim HJ. Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. Front Oncol. 2021 Jul 2;11:608207. doi: 10.3389/fonc.2021.608207. eCollection 2021.'}, {'pmid': '32460816', 'type': 'DERIVED', 'citation': 'Kim HJ, Noh WC, Lee ES, Jung YS, Kim LS, Han W, Nam SJ, Gong G-, Kim HJ, Ahn SH. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. Breast Cancer Res. 2020 May 27;22(1):54. doi: 10.1186/s13058-020-01288-5.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to compare neo-adjuvant therapy of cytotoxic chemotherapy versus GnRHa with tamoxifen , of response rate(RR) in patients of hormone responsive and HER2 negative, lymph node positive, primary breast cancer in premenopausal women.', 'detailedDescription': '1. Primary objective\n\n : Response Rate-MRI and/or Caliper\n2. Secondary objectives\n\n * Pathologic complete response\n * Rate of conservation surgery\n * Ki-67 changes and its relationship to treatment response\n * Length of time to maximum response within the treatment period\n * Tolerability of two treatments\n * Disease-free survival(DFS)\n * Overall survival'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '20 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Histologically proven primary invasive breast cancer which is thought to be suitable for neo-adjuvant treatment\n2. Pathologically proven lymph node positive tumor(FNAB or Core biopsy)\n3. Tumor must be ER positive(eligible patients include Allred score 5 and more, Modified Allred 4 and more) and HER-2 negative(IHC score is 0-1+; If IHC score is 2+, the result of FISH or SISH is negative)\n4. Premenopausal women\n\n Premenopausal status as defined by :\n * Last menses within 6 month of randomization or\n * For patients who have had a unilateral oophorectomy, E2 ≥ 20PG/mL and FSH \\< 30mIU/Ml within 4 weeks of randomization\n5. over 20 years old\n6. Pre-treatment haematology and biochemistry values within acceptable limits :\n\n * ANC ≥ 1.5 × 109/l\n * Hb \\> 9g/dl\n * Platelets ≥ 100 × 109/l\n * AST/ALT ≤ 1.5 × ULN(Upper Limit of Normal)\n * ALP ≤ 1.5 × ULN\n * Serum bilirubin ≤ 1.5 × ULN\n * Serum creatinine ≤ 1.5 × ULN\n7. ECOG PS of 0 or 1\n8. No concomitant medical, psychiatric or geographic problems that might prevent completion of treatment or follow-up\n9. Before any study-specific procedures, the appropriate written informed consent must be obtained\n\nExclusion Criteria:\n\n1. Inflammatory breast cancer\n2. Inoperable disease that is judged very unlikely to be rendered operable by neo-adjuvant treatment\n3. Known severe hypersensitivity to GnRHa treatment\n4. Bilateral invasive breast cancer\n5. Other serious illness or medical condition:\n\n * congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrhythmias\n * history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent\n * active uncontrolled infection\n6. HRT within 4 weeks of starting treatment\n7. Definite contra-indications for the use of corticosteroids.\n8. Last 10 years with a history of other malignant tumor (except in the case of basal cell carcinoma or cervical carcinoma in situ, and where treatment consisted solely of resection)\n9. Systemic metastatic (Tests for the diagnosis of systemic metastatic comply with the guideline in each institution)\n10. Pregnant or breastfeeding women\n11. Chronic oral treatment with corticosteroids unless initiated \\> 6 months prior to study entry and at low dose (≤ 20 mg methylprednisolone or equivalent).'}, 'identificationModule': {'nctId': 'NCT01622361', 'acronym': 'NEST', 'briefTitle': 'Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer', 'organization': {'class': 'OTHER', 'fullName': 'Asan Medical Center'}, 'officialTitle': 'A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer', 'orgStudyIdInfo': {'id': 'KBCSG012'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Chemotherapy Group', 'description': 'Chemotherapy Adriamycin+Cyclophosphamide\\>Docetaxel', 'interventionNames': ['Drug: Adriamycin+Cyclophosphamide>Docetaxel']}, {'type': 'EXPERIMENTAL', 'label': 'Endocrine therapy group', 'description': 'Endocrine therapy(GnRHa with Tamoxifen) group', 'interventionNames': ['Drug: GnRHa with Tamoxifen']}], 'interventions': [{'name': 'Adriamycin+Cyclophosphamide>Docetaxel', 'type': 'DRUG', 'otherNames': ['Chemotherapy'], 'description': '1. Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2\n\n * Route: by slow intravenous bolus\n * Schedule: every 3weeks for 4 cycle\n2. Docetaxel 75mg/m2\n\n * Route: intravenous as per local practice\n * Schedule: every 3weeks for 4 cycle', 'armGroupLabels': ['Chemotherapy Group']}, {'name': 'GnRHa with Tamoxifen', 'type': 'DRUG', 'otherNames': ['Endocrine Therapy'], 'description': '1. Goserelin(GnRHa) 3.6mg\n\n * Route: subcutaneously under the abdominal skin\n * Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)\n2. Tamoxifen 20mg/day\n\n * Route: Oral\n * Schedule: everyday', 'armGroupLabels': ['Endocrine therapy group']}]}, 'contactsLocationsModule': {'locations': [{'zip': '138-736', 'city': 'Seoul', 'state': 'Songpa-gu', 'status': 'RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Ahn Sei Hyun, M.D.', 'role': 'CONTACT', 'email': 'ahnsh@amc.seoul.kr', 'phone': '82-2-3010-3490'}, {'name': 'A. S. Hyun, MD.PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Asan Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}], 'centralContacts': [{'name': 'Ahn Sei Hyun, MD.PhD', 'role': 'CONTACT', 'email': 'ahnsh@amc.seoul.kr', 'phone': '82-2-3010-3490'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Asan Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'Korean Breast Cancer Study Group', 'class': 'OTHER'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'M.D., Ph.D.', 'investigatorFullName': 'Sei-Hyun Ahn', 'investigatorAffiliation': 'Asan Medical Center'}}}}